SCYNEXIS Inc. (NASDAQ: SCYX)
$2.23
+0.0500 ( +2.29% ) 139.2K
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
Market Data
Open
$2.23
Previous close
$2.18
Volume
139.2K
Market cap
$84.25M
Day range
$2.18 - $2.29
52 week range
$1.35 - $3.87
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Jun 21, 2024 |
4 | Insider transactions | 1 | Jun 21, 2024 |
4 | Insider transactions | 1 | Jun 21, 2024 |
4 | Insider transactions | 1 | Jun 21, 2024 |
4 | Insider transactions | 1 | Jun 21, 2024 |
4 | Insider transactions | 1 | Jun 21, 2024 |
8-k | 8K-related | 11 | Jun 20, 2024 |
10-q | Quarterly Reports | 68 | May 08, 2024 |
def | Proxies and info statements | 5 | Apr 25, 2024 |
ars | Annual reports | 1 | Apr 25, 2024 |